(RTTNews) – Biogen Inc. (BIIB) reported Phase 1b clinical data showing that the investigational antisense oligonucleotide therapy, BIIB080, reduced soluble tau protein in cerebrospinal fluid in a dose-dependent and sustained manner in patients with early-stage Alzheimer’s disease. BIIB080 also reduced aggregated tau pathology in all brain composites assessed.
The Phase 2 CELIA study of BIIB080 is in progress and currently recruiting participants in the U.S.
In December 2019, Biogen exercised a license option with Ionis and obtained a worldwide, royalty-bearing license to develop and commercialize BIIB080.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
